Abstract Library

#2263 Patient Survey Devoted to Characterizing Experience and Expectations of Patients with Neuroendocrine Tumors (NET)

Introduction: Patients (pts) with NET experience consequences of disease progression and treatments; their preferences can influence the choice and success of therapeutic strategies.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: SARABI M

Authors: Sarabi M, Gueguen D, Walter T, Hentic O, Baudin E,

Keywords: Patient Report Outcomes, Neuroendocrine Tumor, Quality of life,

#1591 Patient-Reported Preferences in Treatments Approved in Neuroendocrine Tumors: A National Survey from the French Group of Endocrine Tumors

Introduction: Patients with advanced neuroendocrine tumors (NETs) benefit from an increasing number of treatments. The patient’s preference could help physicians to choose among these options

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Thomas W

Authors: Plante A, Baudin E, Do Cao C, Hentic O, Dubreuil O,

Keywords: neuroendocrine tumor, toxicity, PRO,

#916 PET+10 Study: Efficacy of Platin/Etoposide Combination in Well-Differentiated Pancreatic Neuroendocrine Tumors with Ki-67 ≥ 10%

Introduction: Platin-etoposide (PE), the gold standard regimen for poorly differentiated neuroendocrine carcinomas, might be effective in well-differentiated pancreatic neuroendocrine tumors (WD-PNETs) with a high Ki-67 proliferation index.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: BAUDIN E

Authors: Roquin G, Baudin E, Lombard-Bohas C, Cadiot G, Dominguez S,

Keywords: platin/etoposide, pNETs, Ki-67,

#759 Inter-and Intra-Observers Reproducibility of MRI for the Measurement of NET Liver Metastases

Introduction: Assessment of treatment is based on metastases size measurement.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Arfi Rouche J

Authors: Arfi Rouche J, Caramella C, Foulon S, Laplanche A, Baudin E,

Keywords: neuroendocrine, MRI, liver, metastase, reproducibility,

#325 Effect of Everolimus + Octreotide LAR Treatment on 5-Hydroxyindoleacetic Acid Levels in Patients With Advanced Neuroendocrine Tumors: Phase III RADIANT-2 Study Results

Introduction: Urinary 5-hydroxyindoleacetic acid (5-HIAA) is a metabolite and surrogate measure of plasma serotonin, an important cause of carcinoid syndrome in patients with neuroendocrine tumors (NET).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Baudin E, Wolin E, Castellano D, Kaltsas G, Lebrec J,

Keywords: mTOR, everolimus, octreotide, 5-hydroxyindoleacetic acid, 5-HIAA,